Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,902
archived clinical trials in
Irritable Bowel Syndrome (IBS)

Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Pasadena, TX
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Pasadena, TX
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Plano, TX
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
San Antonio, TX
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
San Antonio, TX
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
San Antonio, TX
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Sealy, TX
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Sealy, TX
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Southlake, TX
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Southlake, TX
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Tyler, TX
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Bountiful, UT
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Bountiful, UT
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Ogden, UT
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Ogden, UT
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
West Jordan, UT
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
West Jordan, UT
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Charlottesville, VA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Chesapeake, VA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Danville, VA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Danville, VA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Fairfax, VA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Fairfax, VA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Richmond, VA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Suffolk, VA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Suffolk, VA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Bellevue, WA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Bellevue, WA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Seattle, WA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Spokane, WA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Spokane, WA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Saint Petersburg, FL
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Ocean Springs, MS
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Ocean Springs, MS
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Kettering, OH
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Kettering, OH
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Downingtown, PA
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Downingtown, PA
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
Clinical Research Facility
mi
from
Corsicana, TX
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
Clinical Research Facility
mi
from
Corsicana, TX
Click here to add this to my saved trials
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated:  12/8/2017
mi
from
Berlin,
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
A Study to Assess Repeat Treatment Efficacy and Safety of Rifaximin 550 mg TID in Subjects With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Status: Enrolling
Updated: 12/8/2017
mi
from
Berlin,
Click here to add this to my saved trials
NPDT Evaluation in Children With CFTR and (PSC)
Nasal Potential Difference Testing: Evaluation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Children With Primary Sclerosing Cholangitis (PSC)
Status: Enrolling
Updated:  12/11/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
NPDT Evaluation in Children With CFTR and (PSC)
Nasal Potential Difference Testing: Evaluation of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function in Children With Primary Sclerosing Cholangitis (PSC)
Status: Enrolling
Updated: 12/11/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
Atlanta Gastroenterology Associates
mi
from
Atlanta, GA
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
Atlanta Gastroenterology Associates
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
The University of Chicago Hospitals
mi
from
Chicago, IL
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
The University of Chicago Hospitals
mi
from
Chicago, IL
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
Metropolitan Gastroenterology Group Practice/Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
Metropolitan Gastroenterology Group Practice/Chevy Chase Clinical Research
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
Maryland Digestive Diseases Research
mi
from
Laurel, MD
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
Maryland Digestive Diseases Research
mi
from
Laurel, MD
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
Capitol Gastroenterology Consultants
mi
from
Silver Spring, MD
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
Capitol Gastroenterology Consultants
mi
from
Silver Spring, MD
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
Minnesota Gastroenterology, P.A.
mi
from
Plymouth, MN
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
Minnesota Gastroenterology, P.A.
mi
from
Plymouth, MN
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
Wake Research Associates, LLC
mi
from
Raleigh, NC
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
Wake Research Associates, LLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
University Hospitals of Cleveland
mi
from
Cleveland, OH
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
Avamar Center for Endoscopy
mi
from
Warren, OH
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
Avamar Center for Endoscopy
mi
from
Warren, OH
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
University of Pennsylvania - Presbyterian Medical Center
mi
from
Philadelphia, PA
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
University of Pennsylvania - Presbyterian Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated:  12/14/2017
Atlantic Gastroenterology Associates
mi
from
Egg Harbor Township, NJ
A Trial of Rosiglitazone for Ulcerative Colitis
A Randomized, Placebo-controlled Trial of Rosiglitazone for Treatment of Ulcerative Colitis
Status: Enrolling
Updated: 12/14/2017
Atlantic Gastroenterology Associates
mi
from
Egg Harbor Township, NJ
Click here to add this to my saved trials
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Status: Enrolling
Updated:  1/5/2018
GSK Investigational Site
mi
from
Sherwood, AR
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Status: Enrolling
Updated: 1/5/2018
GSK Investigational Site
mi
from
Sherwood, AR
Click here to add this to my saved trials
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Status: Enrolling
Updated:  1/5/2018
GSK Investigational Site
mi
from
Concord, CA
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Status: Enrolling
Updated: 1/5/2018
GSK Investigational Site
mi
from
Concord, CA
Click here to add this to my saved trials
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Status: Enrolling
Updated:  1/5/2018
GSK Investigational Site
mi
from
Los Angeles, CA
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Status: Enrolling
Updated: 1/5/2018
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Status: Enrolling
Updated:  1/5/2018
GSK Investigational Site
mi
from
Tampa, FL
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Status: Enrolling
Updated: 1/5/2018
GSK Investigational Site
mi
from
Tampa, FL
Click here to add this to my saved trials
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Status: Enrolling
Updated:  1/5/2018
GSK Investigational Site
mi
from
Stockbridge, GA
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Status: Enrolling
Updated: 1/5/2018
GSK Investigational Site
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Status: Enrolling
Updated:  1/5/2018
GSK Investigational Site
mi
from
Louisville, KY
Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome
A Phase 2 PoC in IBS Patients With the CRF1 Receptor Anatgonist, GSK876008
Status: Enrolling
Updated: 1/5/2018
GSK Investigational Site
mi
from
Louisville, KY
Click here to add this to my saved trials